Pihusch et al., 2006 - Google Patents
Endothelial cell–derived microparticles in allogeneic hematopoietic stem cell recipientsPihusch et al., 2006
- Document ID
- 7372628092047727938
- Author
- Pihusch V
- Rank A
- Steber R
- Pihusch M
- Pihusch R
- Toth B
- Hiller E
- Kolb H
- Publication year
- Publication venue
- Transplantation
External Links
Snippet
Background. Alterations of microparticles derived from different cell types are described in a number of diseases associated with inflammation and hemostatic disorders. Methods. In this prospective study, we firstly analyzed endothelial cell derived microparticles (EMP) in 19 …
- 210000002889 Endothelial Cells 0 title abstract description 34
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pihusch et al. | Endothelial cell–derived microparticles in allogeneic hematopoietic stem cell recipients | |
Donne et al. | The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma | |
Pêche et al. | Presentation of donor major histocompatibility complex antigens by bone marrow dendritic cell-derived exosomes modulates allograft rejection1 | |
Spitzer et al. | Combined histocompatibility leukocyte antigenmatched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism | |
Maury et al. | CD4+ CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation | |
Goodman et al. | DIRECT ACTIVATION OF PORCINE ENDOTHELIAL CELLS BY HUMAN NATURAL KILLER CELLS1 | |
Perico et al. | Long-term clinical and immunological profile of kidney transplant patients given mesenchymal stromal cell immunotherapy | |
Weng et al. | Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas | |
Li et al. | Mechanism and localization of CD8 regulatory T cells in a heart transplant model of tolerance | |
Whangbo et al. | The role of regulatory T cells in graft-versus-host disease management | |
Kreisel et al. | Mouse vascular endothelium activates CD8+ T lymphocytes in a B7-dependent fashion | |
Wolf et al. | Regulatory T-cells in the graft and the risk of acute graft-versus-host disease after allogeneic stem cell transplantation | |
Chan et al. | NK cells produce high levels of IL‐10 early after allogeneic stem cell transplantation and suppress development of acute GVHD | |
van den Brink et al. | Graft-versus-host-disease-associated thymic damage results in the appearance of T cell clones with anti-host reactivity1 | |
Paczesny et al. | Acute graft-versus-host disease: new treatment strategies | |
Bishop et al. | Approaching the promise of operational tolerance in clinical transplantation | |
US10106620B2 (en) | Blocking CD38 using anti-CD38 F(ab′)2 to protect NK cells | |
Kanda et al. | In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation | |
Sundin et al. | Multipotent mesenchymal stromal cells express FoxP3: a marker for the immunosuppressive capacity? | |
Mueller | Mechanisms of action of thymoglobulin | |
Craciun et al. | Increased production of interleukin-10 and interleukin-1 receptor antagonist after extracorporeal photochemotherapy in chronic graft-versus-host disease1 | |
Nakai et al. | Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution | |
Mirzakhani et al. | Immunological biomarkers of tolerance in human kidney transplantation: An updated literature review | |
MacDonald et al. | Donor pretreatment with progenipoietin-1 is superior to granulocyte colony–stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation | |
Hotta et al. | Long-term nonhuman primate renal allograft survival without ongoing immunosuppression in recipients of delayed donor bone marrow transplantation |